Company / Capital Expenditures
Actinium Pharmaceuticals, Inc. Capital Expenditures History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$104.0K
FY2025
5-year range
$104.0K / $366.0K
FY2021-FY2025
Trend
-32.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $366,000 to $104,000 over the past 2 years.
Based on SEC 10-K filings.
$104,000 in FY2025 with a 3-year CAGR of -7.9%.
Declined from $366,000 to $104,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -7.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -7.9%, indicating a declining trend.
- In FY2025, capital expenditures decreased 32.0% year-over-year.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $104.0K | -32.0% |
| FY2024 | $153.0K | -58.2% |
| FY2023 | $366.0K | +175.2% |
| FY2022 | $133.0K | -47.4% |
| FY2021 | $253.0K | - |
| FY2011 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026